Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
7,308
archived clinical trials in
Hepatitis

Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Coinfection
A Phase 3, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks in Subjects With Chronic Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Coinfection
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1290
mi
from
New York, NY
Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Coinfection
A Phase 3, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks in Subjects With Chronic Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Coinfection
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1290
mi
from
New York, NY
Click here to add this to my saved trials
Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Coinfection
A Phase 3, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks in Subjects With Chronic Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Coinfection
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1051
mi
from
Durham, NC
Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Coinfection
A Phase 3, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks in Subjects With Chronic Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Coinfection
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1051
mi
from
Durham, NC
Click here to add this to my saved trials
Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Coinfection
A Phase 3, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks in Subjects With Chronic Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Coinfection
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
726
mi
from
Cincinnati, OH
Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Coinfection
A Phase 3, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks in Subjects With Chronic Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Coinfection
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
726
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Coinfection
A Phase 3, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks in Subjects With Chronic Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Coinfection
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1111
mi
from
Richmond, VA
Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Coinfection
A Phase 3, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks in Subjects With Chronic Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Coinfection
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1111
mi
from
Richmond, VA
Click here to add this to my saved trials
Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Coinfection
A Phase 3, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks in Subjects With Chronic Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Coinfection
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1291
mi
from
Bronx, NY
Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Coinfection
A Phase 3, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks in Subjects With Chronic Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Coinfection
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1291
mi
from
Bronx, NY
Click here to add this to my saved trials
A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects
An Open-Label, Multicenter Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Ombitasvir (OBV), Paritaprevir (PTV), Ritonavir (RTV) With or Without Dasabuvir (DSV) and With or Without Ribavirin (RBV) in Pediatric Subjects With Genotype 1 or 4 Chronic Hepatitis C Virus (HCV) Infection (ZIRCON)
Status: Enrolling
Updated:  12/31/1969
University of California, San Francisco /ID# 136774
1341
mi
from
San Francisco, CA
A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects
An Open-Label, Multicenter Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Ombitasvir (OBV), Paritaprevir (PTV), Ritonavir (RTV) With or Without Dasabuvir (DSV) and With or Without Ribavirin (RBV) in Pediatric Subjects With Genotype 1 or 4 Chronic Hepatitis C Virus (HCV) Infection (ZIRCON)
Status: Enrolling
Updated: 12/31/1969
University of California, San Francisco /ID# 136774
1341
mi
from
San Francisco, CA
Click here to add this to my saved trials
A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects
An Open-Label, Multicenter Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Ombitasvir (OBV), Paritaprevir (PTV), Ritonavir (RTV) With or Without Dasabuvir (DSV) and With or Without Ribavirin (RBV) in Pediatric Subjects With Genotype 1 or 4 Chronic Hepatitis C Virus (HCV) Infection (ZIRCON)
Status: Enrolling
Updated:  12/31/1969
Children's Hospital Colorado /ID# 137017
402
mi
from
Aurora, CO
A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects
An Open-Label, Multicenter Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Ombitasvir (OBV), Paritaprevir (PTV), Ritonavir (RTV) With or Without Dasabuvir (DSV) and With or Without Ribavirin (RBV) in Pediatric Subjects With Genotype 1 or 4 Chronic Hepatitis C Virus (HCV) Infection (ZIRCON)
Status: Enrolling
Updated: 12/31/1969
Children's Hospital Colorado /ID# 137017
402
mi
from
Aurora, CO
Click here to add this to my saved trials
A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects
An Open-Label, Multicenter Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Ombitasvir (OBV), Paritaprevir (PTV), Ritonavir (RTV) With or Without Dasabuvir (DSV) and With or Without Ribavirin (RBV) in Pediatric Subjects With Genotype 1 or 4 Chronic Hepatitis C Virus (HCV) Infection (ZIRCON)
Status: Enrolling
Updated:  12/31/1969
University of Florida /ID# 136830
1049
mi
from
Gainesville, FL
A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects
An Open-Label, Multicenter Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Ombitasvir (OBV), Paritaprevir (PTV), Ritonavir (RTV) With or Without Dasabuvir (DSV) and With or Without Ribavirin (RBV) in Pediatric Subjects With Genotype 1 or 4 Chronic Hepatitis C Virus (HCV) Infection (ZIRCON)
Status: Enrolling
Updated: 12/31/1969
University of Florida /ID# 136830
1049
mi
from
Gainesville, FL
Click here to add this to my saved trials
A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects
An Open-Label, Multicenter Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Ombitasvir (OBV), Paritaprevir (PTV), Ritonavir (RTV) With or Without Dasabuvir (DSV) and With or Without Ribavirin (RBV) in Pediatric Subjects With Genotype 1 or 4 Chronic Hepatitis C Virus (HCV) Infection (ZIRCON)
Status: Enrolling
Updated:  12/31/1969
Indiana University /ID# 137015
mi
from
Indianapolis, IN
A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects
An Open-Label, Multicenter Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Ombitasvir (OBV), Paritaprevir (PTV), Ritonavir (RTV) With or Without Dasabuvir (DSV) and With or Without Ribavirin (RBV) in Pediatric Subjects With Genotype 1 or 4 Chronic Hepatitis C Virus (HCV) Infection (ZIRCON)
Status: Enrolling
Updated: 12/31/1969
Indiana University /ID# 137015
mi
from
Indianapolis, IN
Click here to add this to my saved trials
A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects
An Open-Label, Multicenter Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Ombitasvir (OBV), Paritaprevir (PTV), Ritonavir (RTV) With or Without Dasabuvir (DSV) and With or Without Ribavirin (RBV) in Pediatric Subjects With Genotype 1 or 4 Chronic Hepatitis C Virus (HCV) Infection (ZIRCON)
Status: Enrolling
Updated:  12/31/1969
Boston Childrens Hospital /ID# 137174
1441
mi
from
Boston, MA
A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects
An Open-Label, Multicenter Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Ombitasvir (OBV), Paritaprevir (PTV), Ritonavir (RTV) With or Without Dasabuvir (DSV) and With or Without Ribavirin (RBV) in Pediatric Subjects With Genotype 1 or 4 Chronic Hepatitis C Virus (HCV) Infection (ZIRCON)
Status: Enrolling
Updated: 12/31/1969
Boston Childrens Hospital /ID# 137174
1441
mi
from
Boston, MA
Click here to add this to my saved trials
A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects
An Open-Label, Multicenter Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Ombitasvir (OBV), Paritaprevir (PTV), Ritonavir (RTV) With or Without Dasabuvir (DSV) and With or Without Ribavirin (RBV) in Pediatric Subjects With Genotype 1 or 4 Chronic Hepatitis C Virus (HCV) Infection (ZIRCON)
Status: Enrolling
Updated:  12/31/1969
Columbia University Medical Center /ID# 136431
1290
mi
from
New York, NY
A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects
An Open-Label, Multicenter Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Ombitasvir (OBV), Paritaprevir (PTV), Ritonavir (RTV) With or Without Dasabuvir (DSV) and With or Without Ribavirin (RBV) in Pediatric Subjects With Genotype 1 or 4 Chronic Hepatitis C Virus (HCV) Infection (ZIRCON)
Status: Enrolling
Updated: 12/31/1969
Columbia University Medical Center /ID# 136431
1290
mi
from
New York, NY
Click here to add this to my saved trials
A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects
An Open-Label, Multicenter Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Ombitasvir (OBV), Paritaprevir (PTV), Ritonavir (RTV) With or Without Dasabuvir (DSV) and With or Without Ribavirin (RBV) in Pediatric Subjects With Genotype 1 or 4 Chronic Hepatitis C Virus (HCV) Infection (ZIRCON)
Status: Enrolling
Updated:  12/31/1969
Children's Hosp Philadelphia /ID# 137018
mi
from
Philadelphia, PA
A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects
An Open-Label, Multicenter Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Ombitasvir (OBV), Paritaprevir (PTV), Ritonavir (RTV) With or Without Dasabuvir (DSV) and With or Without Ribavirin (RBV) in Pediatric Subjects With Genotype 1 or 4 Chronic Hepatitis C Virus (HCV) Infection (ZIRCON)
Status: Enrolling
Updated: 12/31/1969
Children's Hosp Philadelphia /ID# 137018
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects
An Open-Label, Multicenter Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Ombitasvir (OBV), Paritaprevir (PTV), Ritonavir (RTV) With or Without Dasabuvir (DSV) and With or Without Ribavirin (RBV) in Pediatric Subjects With Genotype 1 or 4 Chronic Hepatitis C Virus (HCV) Infection (ZIRCON)
Status: Enrolling
Updated:  12/31/1969
Baylor College of Medicine /ID# 136590
mi
from
Houston, TX
A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects
An Open-Label, Multicenter Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Ombitasvir (OBV), Paritaprevir (PTV), Ritonavir (RTV) With or Without Dasabuvir (DSV) and With or Without Ribavirin (RBV) in Pediatric Subjects With Genotype 1 or 4 Chronic Hepatitis C Virus (HCV) Infection (ZIRCON)
Status: Enrolling
Updated: 12/31/1969
Baylor College of Medicine /ID# 136590
mi
from
Houston, TX
Click here to add this to my saved trials
A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects
An Open-Label, Multicenter Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Ombitasvir (OBV), Paritaprevir (PTV), Ritonavir (RTV) With or Without Dasabuvir (DSV) and With or Without Ribavirin (RBV) in Pediatric Subjects With Genotype 1 or 4 Chronic Hepatitis C Virus (HCV) Infection (ZIRCON)
Status: Enrolling
Updated:  12/31/1969
Seattle Children's Hospital /ID# 137019
1409
mi
from
Seattle, WA
A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects
An Open-Label, Multicenter Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Ombitasvir (OBV), Paritaprevir (PTV), Ritonavir (RTV) With or Without Dasabuvir (DSV) and With or Without Ribavirin (RBV) in Pediatric Subjects With Genotype 1 or 4 Chronic Hepatitis C Virus (HCV) Infection (ZIRCON)
Status: Enrolling
Updated: 12/31/1969
Seattle Children's Hospital /ID# 137019
1409
mi
from
Seattle, WA
Click here to add this to my saved trials
A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects
An Open-Label, Multicenter Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Ombitasvir (OBV), Paritaprevir (PTV), Ritonavir (RTV) With or Without Dasabuvir (DSV) and With or Without Ribavirin (RBV) in Pediatric Subjects With Genotype 1 or 4 Chronic Hepatitis C Virus (HCV) Infection (ZIRCON)
Status: Enrolling
Updated:  12/31/1969
Cliniques Universitaires Saint Luc /ID# 136910
mi
from
Woluwe-Saint-Lambert,
A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects
An Open-Label, Multicenter Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Ombitasvir (OBV), Paritaprevir (PTV), Ritonavir (RTV) With or Without Dasabuvir (DSV) and With or Without Ribavirin (RBV) in Pediatric Subjects With Genotype 1 or 4 Chronic Hepatitis C Virus (HCV) Infection (ZIRCON)
Status: Enrolling
Updated: 12/31/1969
Cliniques Universitaires Saint Luc /ID# 136910
mi
from
Woluwe-Saint-Lambert,
Click here to add this to my saved trials
A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects
An Open-Label, Multicenter Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Ombitasvir (OBV), Paritaprevir (PTV), Ritonavir (RTV) With or Without Dasabuvir (DSV) and With or Without Ribavirin (RBV) in Pediatric Subjects With Genotype 1 or 4 Chronic Hepatitis C Virus (HCV) Infection (ZIRCON)
Status: Enrolling
Updated:  12/31/1969
Florida Hospital /ID# 167663
mi
from
Orlando, FL
A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects
An Open-Label, Multicenter Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Ombitasvir (OBV), Paritaprevir (PTV), Ritonavir (RTV) With or Without Dasabuvir (DSV) and With or Without Ribavirin (RBV) in Pediatric Subjects With Genotype 1 or 4 Chronic Hepatitis C Virus (HCV) Infection (ZIRCON)
Status: Enrolling
Updated: 12/31/1969
Florida Hospital /ID# 167663
mi
from
Orlando, FL
Click here to add this to my saved trials
A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects
An Open-Label, Multicenter Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Ombitasvir (OBV), Paritaprevir (PTV), Ritonavir (RTV) With or Without Dasabuvir (DSV) and With or Without Ribavirin (RBV) in Pediatric Subjects With Genotype 1 or 4 Chronic Hepatitis C Virus (HCV) Infection (ZIRCON)
Status: Enrolling
Updated:  12/31/1969
Boston Medical Center /ID# 136831
1443
mi
from
Boston, MA
A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects
An Open-Label, Multicenter Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Ombitasvir (OBV), Paritaprevir (PTV), Ritonavir (RTV) With or Without Dasabuvir (DSV) and With or Without Ribavirin (RBV) in Pediatric Subjects With Genotype 1 or 4 Chronic Hepatitis C Virus (HCV) Infection (ZIRCON)
Status: Enrolling
Updated: 12/31/1969
Boston Medical Center /ID# 136831
1443
mi
from
Boston, MA
Click here to add this to my saved trials
Treatment of Chronic Delta Hepatitis With Lonafarnib and Ritonavir
Treatment of Chronic Delta Hepatitis With Lonafarnib and Ritonavir
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
1123
mi
from
Bethesda, MD
Treatment of Chronic Delta Hepatitis With Lonafarnib and Ritonavir
Treatment of Chronic Delta Hepatitis With Lonafarnib and Ritonavir
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
1123
mi
from
Bethesda, MD
Click here to add this to my saved trials
Reversal of Hepatic Impairment in Patients With Hepatitis C Virus (HCV) and Early Decompensation of Cirrhosis
Reversal of Hepatic Impairment by Achieving Sustained Virologic Response (SVR) With 12 Weeks of Simeprevir(SMV)/Sofosbuvir(SOF)/Ribavirin(RBV) in Patients With Hepatitis C Virus (HCV) Genotype 1 Infection and Early Decompensation of Cirrhosis (MELD 10 or Less)
Status: Enrolling
Updated:  12/31/1969
University of Colorado Denver (Leprino Building)
409
mi
from
Denver, CO
Reversal of Hepatic Impairment in Patients With Hepatitis C Virus (HCV) and Early Decompensation of Cirrhosis
Reversal of Hepatic Impairment by Achieving Sustained Virologic Response (SVR) With 12 Weeks of Simeprevir(SMV)/Sofosbuvir(SOF)/Ribavirin(RBV) in Patients With Hepatitis C Virus (HCV) Genotype 1 Infection and Early Decompensation of Cirrhosis (MELD 10 or Less)
Status: Enrolling
Updated: 12/31/1969
University of Colorado Denver (Leprino Building)
409
mi
from
Denver, CO
Click here to add this to my saved trials
Sofosbuvir Based DAA Therapy in HIV/HCV Coinfected Pre or Post Liver Transplant
A Retrospective/Prospective Cohort Study to Assess Safety, Tolerability, and Efficacy of Sofosbuvir Based Direct Acting Antiviral (DAA) Therapy for Hepatitis C Treatment in HIV/HCV Coinfected Subjects Pre or Post Liver Transplant
Status: Enrolling
Updated:  12/31/1969
University of California at San Francisco
1341
mi
from
San Francisco, CA
Sofosbuvir Based DAA Therapy in HIV/HCV Coinfected Pre or Post Liver Transplant
A Retrospective/Prospective Cohort Study to Assess Safety, Tolerability, and Efficacy of Sofosbuvir Based Direct Acting Antiviral (DAA) Therapy for Hepatitis C Treatment in HIV/HCV Coinfected Subjects Pre or Post Liver Transplant
Status: Enrolling
Updated: 12/31/1969
University of California at San Francisco
1341
mi
from
San Francisco, CA
Click here to add this to my saved trials
Sofosbuvir Based DAA Therapy in HIV/HCV Coinfected Pre or Post Liver Transplant
A Retrospective/Prospective Cohort Study to Assess Safety, Tolerability, and Efficacy of Sofosbuvir Based Direct Acting Antiviral (DAA) Therapy for Hepatitis C Treatment in HIV/HCV Coinfected Subjects Pre or Post Liver Transplant
Status: Enrolling
Updated:  12/31/1969
Georgetown University
1127
mi
from
Washington,
Sofosbuvir Based DAA Therapy in HIV/HCV Coinfected Pre or Post Liver Transplant
A Retrospective/Prospective Cohort Study to Assess Safety, Tolerability, and Efficacy of Sofosbuvir Based Direct Acting Antiviral (DAA) Therapy for Hepatitis C Treatment in HIV/HCV Coinfected Subjects Pre or Post Liver Transplant
Status: Enrolling
Updated: 12/31/1969
Georgetown University
1127
mi
from
Washington,
Click here to add this to my saved trials
Sofosbuvir Based DAA Therapy in HIV/HCV Coinfected Pre or Post Liver Transplant
A Retrospective/Prospective Cohort Study to Assess Safety, Tolerability, and Efficacy of Sofosbuvir Based Direct Acting Antiviral (DAA) Therapy for Hepatitis C Treatment in HIV/HCV Coinfected Subjects Pre or Post Liver Transplant
Status: Enrolling
Updated:  12/31/1969
University of Maryland
1148
mi
from
Baltimore, MD
Sofosbuvir Based DAA Therapy in HIV/HCV Coinfected Pre or Post Liver Transplant
A Retrospective/Prospective Cohort Study to Assess Safety, Tolerability, and Efficacy of Sofosbuvir Based Direct Acting Antiviral (DAA) Therapy for Hepatitis C Treatment in HIV/HCV Coinfected Subjects Pre or Post Liver Transplant
Status: Enrolling
Updated: 12/31/1969
University of Maryland
1148
mi
from
Baltimore, MD
Click here to add this to my saved trials
Sofosbuvir Based DAA Therapy in HIV/HCV Coinfected Pre or Post Liver Transplant
A Retrospective/Prospective Cohort Study to Assess Safety, Tolerability, and Efficacy of Sofosbuvir Based Direct Acting Antiviral (DAA) Therapy for Hepatitis C Treatment in HIV/HCV Coinfected Subjects Pre or Post Liver Transplant
Status: Enrolling
Updated:  12/31/1969
Johns Hopkins Medical Center
1149
mi
from
Baltimore, MD
Sofosbuvir Based DAA Therapy in HIV/HCV Coinfected Pre or Post Liver Transplant
A Retrospective/Prospective Cohort Study to Assess Safety, Tolerability, and Efficacy of Sofosbuvir Based Direct Acting Antiviral (DAA) Therapy for Hepatitis C Treatment in HIV/HCV Coinfected Subjects Pre or Post Liver Transplant
Status: Enrolling
Updated: 12/31/1969
Johns Hopkins Medical Center
1149
mi
from
Baltimore, MD
Click here to add this to my saved trials
Sofosbuvir Based DAA Therapy in HIV/HCV Coinfected Pre or Post Liver Transplant
A Retrospective/Prospective Cohort Study to Assess Safety, Tolerability, and Efficacy of Sofosbuvir Based Direct Acting Antiviral (DAA) Therapy for Hepatitis C Treatment in HIV/HCV Coinfected Subjects Pre or Post Liver Transplant
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center
1123
mi
from
Bethesda, MD
Sofosbuvir Based DAA Therapy in HIV/HCV Coinfected Pre or Post Liver Transplant
A Retrospective/Prospective Cohort Study to Assess Safety, Tolerability, and Efficacy of Sofosbuvir Based Direct Acting Antiviral (DAA) Therapy for Hepatitis C Treatment in HIV/HCV Coinfected Subjects Pre or Post Liver Transplant
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center
1123
mi
from
Bethesda, MD
Click here to add this to my saved trials
Sofosbuvir Based DAA Therapy in HIV/HCV Coinfected Pre or Post Liver Transplant
A Retrospective/Prospective Cohort Study to Assess Safety, Tolerability, and Efficacy of Sofosbuvir Based Direct Acting Antiviral (DAA) Therapy for Hepatitis C Treatment in HIV/HCV Coinfected Subjects Pre or Post Liver Transplant
Status: Enrolling
Updated:  12/31/1969
Mt. Sinai Medical Center
1290
mi
from
New York, NY
Sofosbuvir Based DAA Therapy in HIV/HCV Coinfected Pre or Post Liver Transplant
A Retrospective/Prospective Cohort Study to Assess Safety, Tolerability, and Efficacy of Sofosbuvir Based Direct Acting Antiviral (DAA) Therapy for Hepatitis C Treatment in HIV/HCV Coinfected Subjects Pre or Post Liver Transplant
Status: Enrolling
Updated: 12/31/1969
Mt. Sinai Medical Center
1290
mi
from
New York, NY
Click here to add this to my saved trials
Sofosbuvir Based DAA Therapy in HIV/HCV Coinfected Pre or Post Liver Transplant
A Retrospective/Prospective Cohort Study to Assess Safety, Tolerability, and Efficacy of Sofosbuvir Based Direct Acting Antiviral (DAA) Therapy for Hepatitis C Treatment in HIV/HCV Coinfected Subjects Pre or Post Liver Transplant
Status: Enrolling
Updated:  12/31/1969
Columbia University
1290
mi
from
New York, NY
Sofosbuvir Based DAA Therapy in HIV/HCV Coinfected Pre or Post Liver Transplant
A Retrospective/Prospective Cohort Study to Assess Safety, Tolerability, and Efficacy of Sofosbuvir Based Direct Acting Antiviral (DAA) Therapy for Hepatitis C Treatment in HIV/HCV Coinfected Subjects Pre or Post Liver Transplant
Status: Enrolling
Updated: 12/31/1969
Columbia University
1290
mi
from
New York, NY
Click here to add this to my saved trials
Sofosbuvir Based DAA Therapy in HIV/HCV Coinfected Pre or Post Liver Transplant
A Retrospective/Prospective Cohort Study to Assess Safety, Tolerability, and Efficacy of Sofosbuvir Based Direct Acting Antiviral (DAA) Therapy for Hepatitis C Treatment in HIV/HCV Coinfected Subjects Pre or Post Liver Transplant
Status: Enrolling
Updated:  12/31/1969
Univ of Pennsylvania
1223
mi
from
Philadelphia, PA
Sofosbuvir Based DAA Therapy in HIV/HCV Coinfected Pre or Post Liver Transplant
A Retrospective/Prospective Cohort Study to Assess Safety, Tolerability, and Efficacy of Sofosbuvir Based Direct Acting Antiviral (DAA) Therapy for Hepatitis C Treatment in HIV/HCV Coinfected Subjects Pre or Post Liver Transplant
Status: Enrolling
Updated: 12/31/1969
Univ of Pennsylvania
1223
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination With or Without Ribavirin in Participants With Chronic Genotype 1 HCV Infection Previously Treated With a Direct Acting Antiviral Regimen
A Phase 2, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/GS-5816/GS-9857 Fixed-Dose Combination With or Without Ribavirin in Subjects With Chronic Genotype 1 HCV Infection Previously Treated With a Direct Acting Antiviral Regimen
Status: Enrolling
Updated:  12/31/1969
Texas Liver Institute
575
mi
from
San Antonio, TX
Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination With or Without Ribavirin in Participants With Chronic Genotype 1 HCV Infection Previously Treated With a Direct Acting Antiviral Regimen
A Phase 2, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/GS-5816/GS-9857 Fixed-Dose Combination With or Without Ribavirin in Subjects With Chronic Genotype 1 HCV Infection Previously Treated With a Direct Acting Antiviral Regimen
Status: Enrolling
Updated: 12/31/1969
Texas Liver Institute
575
mi
from
San Antonio, TX
Click here to add this to my saved trials
C Tracker, Hepatitis C, Care & Collaboration - Patient Reported Outcomes Survey Study
preSmartphone App for Monitoring and Reporting of Hepatitis C Related Health Information: C Tracker Hepatitis C, Care & Collaboration - Patient Reported Outcomes Survey Study
Status: Enrolling
Updated:  12/31/1969
Children's Hospital Boston
1442
mi
from
Boston, MA
C Tracker, Hepatitis C, Care & Collaboration - Patient Reported Outcomes Survey Study
preSmartphone App for Monitoring and Reporting of Hepatitis C Related Health Information: C Tracker Hepatitis C, Care & Collaboration - Patient Reported Outcomes Survey Study
Status: Enrolling
Updated: 12/31/1969
Children's Hospital Boston
1442
mi
from
Boston, MA
Click here to add this to my saved trials
JKB-121 for the Treatment of Nonalcoholic Steatohepatitis
A Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Phase II Trial of JKB-121 for the Treatment of Nonalcoholic Steatohepatitis (NASH)
Status: Enrolling
Updated:  12/31/1969
Northwestern University Feinberg School of Medicine
611
mi
from
Chicago, IL
JKB-121 for the Treatment of Nonalcoholic Steatohepatitis
A Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Phase II Trial of JKB-121 for the Treatment of Nonalcoholic Steatohepatitis (NASH)
Status: Enrolling
Updated: 12/31/1969
Northwestern University Feinberg School of Medicine
611
mi
from
Chicago, IL
Click here to add this to my saved trials
JKB-121 for the Treatment of Nonalcoholic Steatohepatitis
A Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Phase II Trial of JKB-121 for the Treatment of Nonalcoholic Steatohepatitis (NASH)
Status: Enrolling
Updated:  12/31/1969
Duke University
1052
mi
from
Durham, NC
JKB-121 for the Treatment of Nonalcoholic Steatohepatitis
A Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Phase II Trial of JKB-121 for the Treatment of Nonalcoholic Steatohepatitis (NASH)
Status: Enrolling
Updated: 12/31/1969
Duke University
1052
mi
from
Durham, NC
Click here to add this to my saved trials
JKB-121 for the Treatment of Nonalcoholic Steatohepatitis
A Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Phase II Trial of JKB-121 for the Treatment of Nonalcoholic Steatohepatitis (NASH)
Status: Enrolling
Updated:  12/31/1969
Brook Army Medical Center
569
mi
from
Houston, TX
JKB-121 for the Treatment of Nonalcoholic Steatohepatitis
A Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Phase II Trial of JKB-121 for the Treatment of Nonalcoholic Steatohepatitis (NASH)
Status: Enrolling
Updated: 12/31/1969
Brook Army Medical Center
569
mi
from
Houston, TX
Click here to add this to my saved trials
JKB-121 for the Treatment of Nonalcoholic Steatohepatitis
A Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Phase II Trial of JKB-121 for the Treatment of Nonalcoholic Steatohepatitis (NASH)
Status: Enrolling
Updated:  12/31/1969
University of Virginia Health Systems
1052
mi
from
Charlottesville, VA
JKB-121 for the Treatment of Nonalcoholic Steatohepatitis
A Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Phase II Trial of JKB-121 for the Treatment of Nonalcoholic Steatohepatitis (NASH)
Status: Enrolling
Updated: 12/31/1969
University of Virginia Health Systems
1052
mi
from
Charlottesville, VA
Click here to add this to my saved trials
JKB-121 for the Treatment of Nonalcoholic Steatohepatitis
A Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Phase II Trial of JKB-121 for the Treatment of Nonalcoholic Steatohepatitis (NASH)
Status: Enrolling
Updated:  12/31/1969
Medical College of Virginia
1113
mi
from
Richmond, VA
JKB-121 for the Treatment of Nonalcoholic Steatohepatitis
A Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Phase II Trial of JKB-121 for the Treatment of Nonalcoholic Steatohepatitis (NASH)
Status: Enrolling
Updated: 12/31/1969
Medical College of Virginia
1113
mi
from
Richmond, VA
Click here to add this to my saved trials
JKB-121 for the Treatment of Nonalcoholic Steatohepatitis
A Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Phase II Trial of JKB-121 for the Treatment of Nonalcoholic Steatohepatitis (NASH)
Status: Enrolling
Updated:  12/31/1969
Digestive Disease Specialists of the Southeast
833
mi
from
Dothan, AL
JKB-121 for the Treatment of Nonalcoholic Steatohepatitis
A Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Phase II Trial of JKB-121 for the Treatment of Nonalcoholic Steatohepatitis (NASH)
Status: Enrolling
Updated: 12/31/1969
Digestive Disease Specialists of the Southeast
833
mi
from
Dothan, AL
Click here to add this to my saved trials
JKB-121 for the Treatment of Nonalcoholic Steatohepatitis
A Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Phase II Trial of JKB-121 for the Treatment of Nonalcoholic Steatohepatitis (NASH)
Status: Enrolling
Updated:  12/31/1969
Digestive Associates
963
mi
from
Las Vegas, NV
JKB-121 for the Treatment of Nonalcoholic Steatohepatitis
A Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Phase II Trial of JKB-121 for the Treatment of Nonalcoholic Steatohepatitis (NASH)
Status: Enrolling
Updated: 12/31/1969
Digestive Associates
963
mi
from
Las Vegas, NV
Click here to add this to my saved trials
JKB-121 for the Treatment of Nonalcoholic Steatohepatitis
A Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Phase II Trial of JKB-121 for the Treatment of Nonalcoholic Steatohepatitis (NASH)
Status: Enrolling
Updated:  12/31/1969
Digestive Disease Specialists
725
mi
from
Cincinnati, OH
JKB-121 for the Treatment of Nonalcoholic Steatohepatitis
A Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Phase II Trial of JKB-121 for the Treatment of Nonalcoholic Steatohepatitis (NASH)
Status: Enrolling
Updated: 12/31/1969
Digestive Disease Specialists
725
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Effects of Sofosbuvir/Ledipasvir Treatment on the Pharmacokinetics and Renal Safety of Tenofovir
Effects of Sofosbuvir/Ledipasvir Treatment on the Pharmacokinetics and Renal Safety of Tenofovir
Status: Enrolling
Updated:  12/31/1969
University of Colorado Hospital
400
mi
from
Aurora, CO
Effects of Sofosbuvir/Ledipasvir Treatment on the Pharmacokinetics and Renal Safety of Tenofovir
Effects of Sofosbuvir/Ledipasvir Treatment on the Pharmacokinetics and Renal Safety of Tenofovir
Status: Enrolling
Updated: 12/31/1969
University of Colorado Hospital
400
mi
from
Aurora, CO
Click here to add this to my saved trials
A Prospective, Longitudinal Study of Endothelial Function in HIV/HCV Coinfected Subjects
Clinical and Translational Science Institute Prospective Longitudinal Assessment of Coinfected Subjects With HIV/Hepatitis C for Endothelial Function Study
Status: Enrolling
Updated:  12/31/1969
UCLA CARE Ctr
1170
mi
from
Los Angeles, CA
A Prospective, Longitudinal Study of Endothelial Function in HIV/HCV Coinfected Subjects
Clinical and Translational Science Institute Prospective Longitudinal Assessment of Coinfected Subjects With HIV/Hepatitis C for Endothelial Function Study
Status: Enrolling
Updated: 12/31/1969
UCLA CARE Ctr
1170
mi
from
Los Angeles, CA
Click here to add this to my saved trials
The Patient-Reported Outcomes Project of HCV-TARGET
The Patient-Reported Outcomes Project of HCV-TARGET (PROP UP)
Status: Enrolling
Updated:  12/31/1969
Yale University
1344
mi
from
New Haven, CT
The Patient-Reported Outcomes Project of HCV-TARGET
The Patient-Reported Outcomes Project of HCV-TARGET (PROP UP)
Status: Enrolling
Updated: 12/31/1969
Yale University
1344
mi
from
New Haven, CT
Click here to add this to my saved trials
The Patient-Reported Outcomes Project of HCV-TARGET
The Patient-Reported Outcomes Project of HCV-TARGET (PROP UP)
Status: Enrolling
Updated:  12/31/1969
University of Florida
1049
mi
from
Gainesville, FL
The Patient-Reported Outcomes Project of HCV-TARGET
The Patient-Reported Outcomes Project of HCV-TARGET (PROP UP)
Status: Enrolling
Updated: 12/31/1969
University of Florida
1049
mi
from
Gainesville, FL
Click here to add this to my saved trials
The Patient-Reported Outcomes Project of HCV-TARGET
The Patient-Reported Outcomes Project of HCV-TARGET (PROP UP)
Status: Enrolling
Updated:  12/31/1969
Rush University
608
mi
from
Chicago, IL
The Patient-Reported Outcomes Project of HCV-TARGET
The Patient-Reported Outcomes Project of HCV-TARGET (PROP UP)
Status: Enrolling
Updated: 12/31/1969
Rush University
608
mi
from
Chicago, IL
Click here to add this to my saved trials
The Patient-Reported Outcomes Project of HCV-TARGET
The Patient-Reported Outcomes Project of HCV-TARGET (PROP UP)
Status: Enrolling
Updated:  12/31/1969
University of Michigan
808
mi
from
Ann Arbor, MI
The Patient-Reported Outcomes Project of HCV-TARGET
The Patient-Reported Outcomes Project of HCV-TARGET (PROP UP)
Status: Enrolling
Updated: 12/31/1969
University of Michigan
808
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
The Patient-Reported Outcomes Project of HCV-TARGET
The Patient-Reported Outcomes Project of HCV-TARGET (PROP UP)
Status: Enrolling
Updated:  12/31/1969
University of North Carolina at Chapel Hill
1038
mi
from
Chapel Hill, NC
The Patient-Reported Outcomes Project of HCV-TARGET
The Patient-Reported Outcomes Project of HCV-TARGET (PROP UP)
Status: Enrolling
Updated: 12/31/1969
University of North Carolina at Chapel Hill
1038
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
The Patient-Reported Outcomes Project of HCV-TARGET
The Patient-Reported Outcomes Project of HCV-TARGET (PROP UP)
Status: Enrolling
Updated:  12/31/1969
Univ of Pennsylvania
1223
mi
from
Philadelphia, PA
The Patient-Reported Outcomes Project of HCV-TARGET
The Patient-Reported Outcomes Project of HCV-TARGET (PROP UP)
Status: Enrolling
Updated: 12/31/1969
Univ of Pennsylvania
1223
mi
from
Philadelphia, PA
Click here to add this to my saved trials
The Patient-Reported Outcomes Project of HCV-TARGET
The Patient-Reported Outcomes Project of HCV-TARGET (PROP UP)
Status: Enrolling
Updated:  12/31/1969
Virginia Commonwealth University
1113
mi
from
Richmond, VA
The Patient-Reported Outcomes Project of HCV-TARGET
The Patient-Reported Outcomes Project of HCV-TARGET (PROP UP)
Status: Enrolling
Updated: 12/31/1969
Virginia Commonwealth University
1113
mi
from
Richmond, VA
Click here to add this to my saved trials
The Patient-Reported Outcomes Project of HCV-TARGET
The Patient-Reported Outcomes Project of HCV-TARGET (PROP UP)
Status: Enrolling
Updated:  12/31/1969
University of California Davis
1296
mi
from
Davis, CA
The Patient-Reported Outcomes Project of HCV-TARGET
The Patient-Reported Outcomes Project of HCV-TARGET (PROP UP)
Status: Enrolling
Updated: 12/31/1969
University of California Davis
1296
mi
from
Davis, CA
Click here to add this to my saved trials
The Patient-Reported Outcomes Project of HCV-TARGET
The Patient-Reported Outcomes Project of HCV-TARGET (PROP UP)
Status: Enrolling
Updated:  12/31/1969
St. Louis University
415
mi
from
Saint Louis, MO
The Patient-Reported Outcomes Project of HCV-TARGET
The Patient-Reported Outcomes Project of HCV-TARGET (PROP UP)
Status: Enrolling
Updated: 12/31/1969
St. Louis University
415
mi
from
Saint Louis, MO
Click here to add this to my saved trials
The Patient-Reported Outcomes Project of HCV-TARGET
The Patient-Reported Outcomes Project of HCV-TARGET (PROP UP)
Status: Enrolling
Updated:  12/31/1969
Asheville Gastroenterology Associates, P.A.
857
mi
from
Asheville, NC
The Patient-Reported Outcomes Project of HCV-TARGET
The Patient-Reported Outcomes Project of HCV-TARGET (PROP UP)
Status: Enrolling
Updated: 12/31/1969
Asheville Gastroenterology Associates, P.A.
857
mi
from
Asheville, NC
Click here to add this to my saved trials
The Patient-Reported Outcomes Project of HCV-TARGET
The Patient-Reported Outcomes Project of HCV-TARGET (PROP UP)
Status: Enrolling
Updated:  12/31/1969
Wilmington Gastroenterology Associates
1134
mi
from
Wilmington, NC
The Patient-Reported Outcomes Project of HCV-TARGET
The Patient-Reported Outcomes Project of HCV-TARGET (PROP UP)
Status: Enrolling
Updated: 12/31/1969
Wilmington Gastroenterology Associates
1134
mi
from
Wilmington, NC
Click here to add this to my saved trials